Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism
Jiaying Lu,Weiqi Bao,Ming Li,Ling Li,Zhengwei Zhang,Jiong Song,Ian Alberts,Matthias Brendel,Paul Cumming,Chuantao Zuo,Yihui Guan,Qianhua Zhao,Axel Rominger
2020-01-01
Journal of Nuclear Medicine
Abstract:1549 Objectives: Molecular imaging of tauopathies is complicated by the differing specificities and off-target binding properties of available ligands for positron-emission-tomography (PET). [18F]-APN-1607 ([18F]-PM-PBB3) is a newly developed tau tracer. The aim of the study was to characterize the imaging properties of [18F]-APN-1607 in Alzheimer’s disease (AD) patients compared to normal control (NC) subjects.\n Methods: We obtained PET recordings with [18F]-APN-1607 and [18F]-FDG in patients with a clinical diagnosis of AD group (N=19, 61.83±11.89 y,7 male/12 female), along with an age-matched NC group ([18F]-APN-1607 only, N=11, 61.79±4.64 y, 7 male/4 female). Meanwhile, all subjects underwent anatomical magnetic resonance imaging (MRI) within one month. The tosylate precursor used for the synthesis of [18F]-APN-1607 was provided by APRINOIA Therapeutics (Suzhou, China) and the synthesis was prepared in Huashan hospital (Shanghai, China). Using statistical parametric mapping (SPM) and volume of interest (VOI) (PMOD Version 4.005 (PMOD Technologies Ltd., Zurich, Switzerland)) analyses of the reference region normalized standard uptake value (SUV) maps, we then tested for group differences and relationships between two modes of PET as well as clinical general cognition.\n Results: We found that, for the AD group, [18F]-APN-1607 binding was elevated in widespread cortical regions (Figure1) (P\u003c0.001 for VOI analysis(Figure2), family wise error-corrected P\u003c0.01 for SPM analysis(Figure3)) and correlated negatively with mini-mental state examination (MMSE) score (frontal lobe: R=-0.632, P=0.004; temporal lobe: R=-0.593, P=0.008; parietal lobe: R=-0.552, P=0.014; insula: R=-0.650, P=0.003; cingulum: R=-0.665, P=0.002) except occipital lobe (R=-0.417, P=0.076). The hypometabolism in signature areas of AD also showed correlations with regional [18F]-APN-1607 bindings (frontal lobe: R=-0.421, P=0.073; temporal lobe: R=-0.530, P=0.020; parietal lobe: R=-0.637, P=0.003).\n Conclusions: Our results suggest that [18F]-APN-1607 detects tau deposition in AD effectively, correlating with metabolism and cognitive function.